ARL10 Activators
ARL10 Activators function through various biochemical mechanisms to enhance its activity, with a notable influence being exerted through the modulation of cyclic AMP levels. Activation of adenylyl cyclase through direct agonism or inhibition of cAMP degradation leads to a surge in cAMP, which subsequently activates PKA. PKA can phosphorylate a range of proteins, and in this context, it is implicated in the phosphorylation that amplifies ARL10 activity. Furthermore, the use of a non-hydrolyzable GTP analog suggests an engagement with GTP-binding proteins, potentially intensifying the intrinsic GTPase activity of ARL10. The strategic inhibition of PKA can also serve as an indirect confirmation of the kinase's role in activating ARL10. When PKA activity is inhibited and then reversed, the consequential changes in ARL10 activity may affirm its dependence on PKA-mediated phosphorylation.
Additional mechanisms involve modulating intracellular conditions that are conducive to the optimal functioning of ARL10. For instance, lysosomal alkalinization through weak bases could affect ARL10's localization, thereby influencing its activity within cellular compartments where it exerts its function. The increase in intracellular zinc concentration through the use of an ionophore can affect GTPase activity, which aligns with the biochemical nature of ARL10, potentially leading to its enhanced functional state. The antagonism of specific G-protein-coupled receptors can cause downstream alterations in G-protein signaling, which might culminate in the modulation of ARL10 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Phosphodiesterase 4 inhibitor which prevents the breakdown of cAMP, thereby sustaining PKA activity that may enhance the phosphorylation and activation of ARL10. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-selective inhibitor of phosphodiesterases, increases intracellular cAMP levels, thereby promoting PKA-mediated activation of ARL10. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Stimulates adrenergic receptors leading to adenylyl cyclase activation. The resulting rise in cAMP levels can enhance PKA activity and subsequent activation of ARL10. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic agonist that activates adenylyl cyclase, raising cAMP levels and potentially facilitating PKA-mediated activation of ARL10. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Membrane-permeable cAMP analog that directly activates PKA, which may enhance the phosphorylation and activity of ARL10. | ||||||
Guanosine 5′-O-(3-thiotriphosphate) tetralithium salt | 94825-44-2 | sc-202639 | 10 mg | $465.00 | ||
Non-hydrolyzable GTP analog that can activate GTP-binding proteins and potentially enhance the GTPase activity of ARL10. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
PKA inhibitor that can be used to indirectly demonstrate the PKA-dependent activation of ARL10 when reversed, suggesting that PKA phosphorylation activates ARL10. | ||||||
Ammonium Chloride | 12125-02-9 | sc-202936 sc-202936A sc-202936B | 25 g 500 g 2.5 kg | $39.00 $55.00 $150.00 | 4 | |
Weak base that can cause lysosomal alkalinization, potentially affecting ARL10 localization and function due to its role in lysosomal processes. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Ionophore that increases intracellular zinc concentration, which can modulate GTPase activity and potentially enhance the function of ARL10. | ||||||